Drugs targeting immune checkpoint inhibitor pathways have shown tremendous promise in treating various types of cancer and have been highly effective in a number of patients. However, for a subset of cancer patients this new type of treatment approach has failed to work. Recently, a series of landmark studies demonstrated that the efficacy of immune checkpoint inhibitor therapies is dependent upon the presence of specific gut bacteria1-3.... Read More